Article
Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).
Vaccine - 4 Oct 2002
Watanabe Izumi, Hagiwara Yukari, Kadowaki Shin-etsu, Yoshikawa Tomoki, Komase Katsuhiro, Aizawa Chikara, Kiyono Hiroshi, Takeda Yoshifumi, McGhee Jerry R, Chiba Joe, Sata Tetsutaro, Kurata Takeshi, Tamura Shin-ichi
Abstract excerpt
Immune responses induced by a nasal influenza vaccine with a mutant cholera toxin (CT112K), known to be a safe adjuvant, were characterized in BALB/c mice to confirm the most suitable regimen of this vaccine for humans. Mice received a primary intranasal administration of the adjuvant (0.1 micro g)-combined PR8 vaccine (0.1 micro g) and a secondary administration of the PR8 vaccine alone (0.1 micro g) 4 weeks...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.